NEW YORK (GenomeWeb News) – Enzymatics today announced it has bought ArcherDx, a developer of kits and software solutions for next-generation sequencing, for up to $50 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.